Altimmune cuts hepatitis B program, highlights muscle preservation on obesity drug in data update
Altimmune is ending its hepatitis B program following a trial failure, raising the stakes on its only remaining candidate in the pipeline — an injectable GLP-1/glucagon dual agonist for obesity and MASH — for which it also revealed new data Wednesday. The company said that the overall response in its